Is combination therapy with diverse anti-diabetic drugs associated with better kidney outcomes? To investigate this, a study compared the risk of major adverse kidney events (MAKE) between monotherapy and combination therapy in patients with diabetes and HbA1c β‰₯7%. The study included 3,475 matched participants in each treatment group from the UK Biobank and 261 monotherapy and 808 combination therapy participants from the Chongqing Diabetes Registry.

Eligible participants received biguanides, insulin, Ξ±-glucosidase inhibitors, sulfonylureas, glinides, or thiazolidinediones as monotherapy or in combinations of two or more drugs at baseline. While no patients in the UK Biobank cohort had received DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists, these drug classes were used by 1.6% of patients in the monotherapy group and 56.4% of those in the combination therapy group in…